Eli Lilly and Company Reports Strong Q2 2026 Financial Results and Raises Full-Year Guidance

Summary

Eli Lilly and Company reported robust second-quarter 2026 financial results on August 5, 2026, via Ex. 99.1 press release. Revenue increased 48% to $23.0 billion, primarily driven by Mounjaro and Zepbound volume. Reported EPS rose 26% to $7.94, while non-GAAP EPS increased 33% to $8.38. The company also raised its full-year 2026 revenue guidance to a range of $85.0 billion to $87.0 billion. * Raised underlying non-GAAP EPS guidance for the full year by $2.78 at the midpoint, resulting in an updated range of $35.50 to $36.50, despite $3.03 of acquired IPR&D charges. * Received U.S. FDA approval of Ebglyss for one maintenance dose every eight weeks in moderate-to-severe atopic dermatitis. * Secured European Commission approval of Jaypirca as monotherapy for adults with chronic lymphocytic leukemia.

Why It Matters

These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.

Key Quote

“Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated August 5, 2026, announcing the financial results of Eli Lilly and Company for the quarter ended June 30, 2026.”

— From Item 2.02

Filing Details